Quick Answer
Aclaris Therapeutics, Inc. reported R&D Expense of $52.65 million for fiscal year 2025.
Aclaris Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $52.65M | +56.7% |
| 2024 | $33.59M | -65.9% |
| 2023 | $98.38M | +26.4% |
| 2022 | $77.81M | +77.6% |
| 2021 | $43.81M | +49.3% |
| 2020 | $29.34M | -54.3% |
| 2019 | $64.17M | +5.5% |
| 2018 | $60.84M | +69.9% |
| 2017 | $35.80M | +7.0% |
| 2016 | $33.48M | +118.2% |
| 2015 | $15.34M | +135.7% |
| 2014 | $6.51M | +86.6% |
| 2013 | $3.49M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.03M | +118.7% | +13.8% |
| June 30, 2025 | $11.45M | +30.7% | -1.2% |
| March 31, 2025 | $11.58M | +17.7% | +94.5% |
| September 30, 2024 | $5.96M | -75.1% | -32.0% |
| June 30, 2024 | $8.76M | -65.3% | -11.0% |
| March 31, 2024 | $9.85M | -56.4% | -58.8% |
| September 30, 2023 | $23.88M | +0.9% | -5.5% |
| June 30, 2023 | $25.27M | +34.6% | +11.9% |
- Aclaris Therapeutics, Inc. showed an increase of +56.7% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, Aclaris Therapeutics, Inc.’s r&d expense has grown by 1409.3% (from $3.49 million to $52.65 million).
- The most recent figure is from Aclaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: